• Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. 

  Witkiewicz, AK; Chung, S; Brough, R; Vail, P; Franco, J; Lord, CJ; Knudsen, ES (2018-01)

  Approximately 30% of triple-negative breast cancers (TNBCs) exhibit functional loss of the RB tumor suppressor, suggesting a target for precision intervention. Here, we use drug screens to identify agents specifically ...
• CancerGD: a resource for identifying and interpreting genetic dependencies in cancer 

  Bridgett, S; Campbell, J; Lord, C; Ryan, C (2016-10-26)

  Abstract Genes whose function is selectively essential in the presence of cancer associated genetic aberrations represent promising targets for the development of precision therapeutics. Here we present CancerGD ( ...
• Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. 

  Quigley, D; Alumkal, JJ; Wyatt, AW; Kothari, V; Foye, A; Lloyd, P; Aggarwal, R; Kim, W; Lu, E; Schwartzman, J; Beja, K; Annala, M; Das, R; Diolaiti, M; Pritchard, C; Thomas, G; Tomlins, S; Knudsen, K; Lord, CJ; Ryan, C; Youngren, J; Beer, TM; Ashworth, A; Small, EJ; Feng, FY (2017-09)

  Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as BRCA2 HRR defects confer synthetic lethality to PARP inhibitors (PARPi) ...
• Autoinhibition Mechanism of the Ubiquitin-Conjugating Enzyme UBE2S by Autoubiquitination. 

  Liess, AKL; Kucerova, A; Schweimer, K; Yu, L; Roumeliotis, TI; Diebold, M; Dybkov, O; Sotriffer, C; Urlaub, H; Choudhary, JS; Mansfeld, J; Lorenz, S (2019-08)

  Ubiquitin-conjugating enzymes (E2s) govern key aspects of ubiquitin signaling. Emerging evidence suggests that the activities of E2s are modulated by posttranslational modifications; the structural underpinnings, however, ...
• Life after covid for cancer clinical trials 

  Hall, E; Lewis, R; Snowdon, C

View more